This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Contract research organizations (CROs) and pharmaceutical companies can leverage these cutting-edge technologies to streamline clinical trials and introduce automation in drug discovery. As clinical trials grow in complexity, the volume of data being gathered and utilized for these studies is expanding.
Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.
Drug Pricing, Global Diversity Strategies, & Emerging AI Applications Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for the year ahead.
Breaking the Barriers: How Inaccurate Trial Records Are Delaying Drug Development and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.
Trusted Advisors for Scientific Exchange As pharmaceuticals strive to create medications that are more effective and accessible, it’s essential that they engage HCPs early in order to understand the needs of their target audiences.
In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. Aside from some very brief demos on code generation and literature searches, mentions of LLM applications in preclinical research were scarce. increase in AUC-PR over internal models.
How will AI impact clinical trials? Every year, we take a look at annual predictions to help life sciences, pharmaceutical, and healthcare companies understand larger industry trends and dynamics to prepare for the new year. Will FDA legislation improve diversity? What platforms will key opinion leaders adopt?
How will AI impact clinical trials? Every year, we take a look at annual predictions to help life sciences, pharmaceutical, and healthcare companies understand larger industry trends and dynamics to prepare for the new year. The FDA will enact laws that will supercharge diversity in clinical trials.
Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. When time is of the essence, like in a global pandemic, how do you scale trials internationally for success? Additionally, clinical trials are no longer confined to one country or region.
.: Hands-on training course Webinar/Seminar ( OPEN ) EMA 6/03/2024 6/03/2024 EUCOPE’s Life Science Lectures – Episode Five (Joint Clinical Assessments) Webinar/Seminar ( OPEN ) EUCOPE 6/04/2024 6/04/2024 EUDAMED, the pathway to compliance Webinar/Seminar ( OPEN ) Team Person Responsible for Regulatory Compliance (TEAM-PPRC) 6/04/2024 6/04/2024 News (..)
A live demo is available online, but “it chews through OpenAI credits,” Patel says. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources. “Every query is like $2.” A Mycoplasma cell.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources. “Every query is like $2.” A Mycoplasma cell.
Comment periods for EMA documents (such as concept, reflection, and guidance papers) generally stay open for at least six months, though these timelines can vary drastically. policy, such as public registers, drafts, reflection papers, concept papers, and guidance documents expected into Q1 2024.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content